Beta-blocker study for early-stage liver scarring
Treatments studied
Part of Digestive system clinical trials.
This study tests a medicine called carvedilol (a non-selective beta-blocker) to see if it can prevent complications in people with advanced chronic liver disease who are at high risk but haven't had serious problems like bleeding yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with chronic liver disease caused by alcohol, hepatitis B, hepatitis C, or fatty liver disease (MASLD).
- Your liver stiffness measurement and platelet count must show you are at high risk for developing serious liver problems, as defined by specific medical criteria.
- You must not have moderate-to-large esophageal varices (enlarged veins in the food pipe) or any other serious liver complications like cirrhosis with fluid buildup, bleeding, or brain issues.
- You are not currently taking a non-selective beta-blocker (like carvedilol or propranolol) and have not taken one in the last 6 months.
- You do not have conditions that make beta-blockers unsafe, such as slow heart rate, low blood pressure, asthma, or certain heart blocks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is checking if it is safe for people with cirrhosis (liver scarring) to stop taking a certain blood pressure medicine (non-selective beta blockers) if their main liver problem is under control. If you've had varices or bleeding in the past and your liver is now stable, this trial will see if you can safely stop the medicine.
This trial tests if the drug carvedilol can prevent liver-related emergencies or death in people with cirrhosis and high blood pressure in the liver. It may help those who are stable right now but at risk for a sudden worsening.
This trial tests whether a medicine called carvedilol can lower high blood pressure in the liver veins of people with cirrhosis. It uses a special ultrasound probe to measure the pressure before and after taking the medicine.
This trial tests whether adding metformin to carvedilol (a standard drug) lowers liver pressure more than carvedilol alone in people with cirrhosis who have had variceal bleeding. The goal is to prevent future bleeding.
This trial tests whether carvedilol or propranolol works better to prevent another bleeding episode from enlarged veins in the stomach or esophagus (varices) after they have been treated with endoscopy. If you have cirrhosis and had a variceal bleed 6 to 30 days ago, this study may help find the most effective medicine for you.
This trial tests whether adding a statin (simvastatin) to the usual heart medication carvedilol helps people with both cirrhosis and a related heart problem live longer and avoid serious liver complications.
Hear when a new Portal Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.